甲状腺がん治療薬市場：薬剤別（カボザンチニブ-S-マレート、カプレッサ、コメトリク）、エンドユーザー別（病院、がん専門クリニック、調査機関）-世界予測2023-2030年

甲状腺がん治療薬の世界市場は、2023年にCAGR 10.53%で6億8,514万米ドルと予測され、2030年には13億8,270万米ドルと驚異的な成長を遂げると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の甲状腺がん治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.甲状腺がん治療薬の世界市場規模および予測は？

2.予測期間中、世界の甲状腺がん治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.甲状腺がん治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.甲状腺がん治療薬の世界市場における競争戦略は？

5.甲状腺がん治療薬の世界市場における技術動向と規制の枠組みは？

6.甲状腺がん治療薬の世界市場における主要ベンダーの市場シェアは？

7.甲状腺がん治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で甲状腺がんの有病率が増加
    • 早期診断と治療への注目の高まり
    • 民間団体ががん検診プログラムを拡大
  • 抑制要因
    • 熟練労働者の不足と手順の標準化
  • 機会
    • がんに対する意識の向上と償還政策のイントロダクションを促進する政府の有利な取り組み
    • 治療手順の継続的な進歩と質の向上
  • 課題
    • 政府による厳格な医薬品承認手続き
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 甲状腺がん治療薬市場薬物別

• カボザンチニブ-S-リンゴ酸
• カプレルサ
• コメトリック
• 塩酸ドキソルビシン
• イピリムマブ
• メシル酸レンバチニブ
• ニボルマブ
• バンデタニブ

第7章 甲状腺がん治療薬市場：エンドユーザー別

• 病院
• 腫瘍科クリニック
• 調査機関

第8章 南北アメリカの甲状腺がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の甲状腺がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの甲状腺がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. THYROID CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. THYROID CANCER DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
• FIGURE 5. THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 6. THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. THYROID CANCER DRUGS MARKET DYNAMICS
• FIGURE 8. THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 5. THYROID CANCER DRUGS MARKET SIZE, BY CABOZANTINIB-S-MALATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. THYROID CANCER DRUGS MARKET SIZE, BY CAPRELSA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. THYROID CANCER DRUGS MARKET SIZE, BY COMETRIQ, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. THYROID CANCER DRUGS MARKET SIZE, BY DOXORUBICIN HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. THYROID CANCER DRUGS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. THYROID CANCER DRUGS MARKET SIZE, BY LENVATINIB MESYLATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. THYROID CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. THYROID CANCER DRUGS MARKET SIZE, BY VANDETANIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 14. THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 25. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 37. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. INDIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 39. INDIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 74. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. POLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. POLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. QATAR THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 84. QATAR THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 104. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 105. THYROID CANCER DRUGS MARKET LICENSE & PRICING

The Global Thyroid Cancer Drugs Market is forecasted to grow significantly, with a projected USD 685.14 million in 2023 at a CAGR of 10.53% and expected to reach a staggering USD 1,382.70 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Thyroid Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Thyroid Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Cabozantinib-S-Malate, Caprelsa, Cometriq, Doxorubicin Hydrochloride, Ipilimumab, Lenvatinib Mesylate, Nivolumab, and Vandetanib. The Cabozantinib-S-Malate is projected to witness significant market share during forecast period.

Based on End User, market is studied across Hospitals, Oncology Clinics, and Research Organizations. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Thyroid Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Thyroid Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Thyroid Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Thyroid Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Thyroid Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Thyroid Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Thyroid Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Thyroid Cancer Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Thyroid Cancer Drugs Market, by Drug, 2022 vs 2030
• 4.3. Thyroid Cancer Drugs Market, by End User, 2022 vs 2030
• 4.4. Thyroid Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of thyroid cancer cases across the globe
    • 5.1.1.2. Increasing focus on early diagnosis and treatment
    • 5.1.1.3. Private organizations increasing cancer screening programs
  • 5.1.2. Restraints
    • 5.1.2.1. Dearth of skilled workers and standardization of the procedure
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
    • 5.1.3.2. Ongoing advancements in treatment procedures with improved quality
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government drug approval procedures
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Thyroid Cancer Drugs Market, by Drug

• 6.1. Introduction
• 6.2. Cabozantinib-S-Malate
• 6.3. Caprelsa
• 6.4. Cometriq
• 6.5. Doxorubicin Hydrochloride
• 6.6. Ipilimumab
• 6.7. Lenvatinib Mesylate
• 6.8. Nivolumab
• 6.9. Vandetanib

7. Thyroid Cancer Drugs Market, by End User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Oncology Clinics
• 7.4. Research Organizations

8. Americas Thyroid Cancer Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Thyroid Cancer Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Thyroid Cancer Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing